文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

早期脓毒性休克患者的生活质量与1年生存率:澳大利亚与新西兰脓毒症复苏评估试验的长期随访

Quality of Life and 1-Year Survival in Patients With Early Septic Shock: Long-Term Follow-Up of the Australasian Resuscitation in Sepsis Evaluation Trial.
PubMed 文献 · Crit Care Med · 2019-01-01
一句话结论急诊早期脓毒性休克患者中,早期目标导向治疗与常规治疗相比未降低6个月和12个月死亡率,也未改善生活质量。

该研究为前瞻性随机平行组试验的长期随访,纳入澳大利亚、新西兰、芬兰、香港和爱尔兰51家医院急诊科2008年10月至2014年4月就诊的1591例早期脓毒性休克患者,比较早期目标导向治疗与常规治疗。6个月死亡率早期目标导向治疗组21.8% vs 常规治疗组22.6%(p=0.70),12个月死亡率26.4% vs 27.9%(p=0.50),均无显著差异。6个月和12个月健康相关生活质量两组间也无差异,12个月时EuroQoL-5D-3L效用评分早期目标导向治疗组0.65±0.33 vs 常规治疗组0.64±0.34(p=0.50),但两组生活质量均显著低于人群常模。

要点

  • 急诊早期脓毒性休克患者中,早期目标导向治疗与常规治疗6个月死亡率无显著差异(21.8% vs 22.6%,p=0.70)。
  • 12个月死亡率两组无显著差异(早期目标导向治疗26.4% vs 常规治疗27.9%,p=0.50)。
  • 6个月和12个月健康相关生活质量两组间无差异,12个月EuroQoL-5D-3L效用评分0.65±0.33 vs 0.64±0.34(p=0.50)。
  • 两组患者健康相关生活质量均显著低于人群常模。

适用人群与场景

  • 2008年10月至2014年4月期间就诊于澳大利亚、新西兰、芬兰、香港和爱尔兰51家医院急诊科的早期脓毒性休克患者,共1591例,纳入澳大利亚与新西兰脓毒症复苏评估试验。

处置流程与药物剂量

  • 干预为早期目标导向治疗,对照为常规治疗。

研究设计与关键结果

  • 研究类型为前瞻性随机平行组试验的长期随访,纳入51家医院1591例急诊早期脓毒性休克患者,比较早期目标导向治疗与常规治疗。
  • 6个月死亡率早期目标导向治疗组21.8% vs 常规治疗组22.6%(p=0.70),无显著差异。
  • 12个月死亡率早期目标导向治疗组26.4% vs 常规治疗组27.9%(p=0.50),无显著差异。
  • 6个月和12个月健康相关生活质量两组间无差异,12个月EuroQoL-5D-3L效用评分早期目标导向治疗组0.65±0.33 vs 常规治疗组0.64±0.34(p=0.50)。
  • 两组健康相关生活质量均显著低于人群常模。

证据类型、等级与局限

  • 证据类型为前瞻性随机平行组试验的长期随访。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在急诊早期脓毒性休克患者中,早期目标导向治疗与常规治疗相比未降低6个月和12个月死亡率,也未改善健康相关生活质量。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To examine long-term survival and quality of life of patients with early septic shock.

DESIGN: Prospective, randomized, parallel-group trial.

SETTING: Fifty-one hospitals in Australia, New Zealand, Finland, Hong Kong, and the Republic of Ireland.

PATIENTS: One-thousand five-hundred ninety-one patients who presented to the emergency department with early septic shock between October 2008 and April 2014, and were enrolled in the Australasian Resuscitation in Sepsis Evaluation trial.

INTERVENTIONS: Early goal-directed therapy versus usual care.

MEASUREMENTS AND MAIN RESULTS: Long-term survival was measured up to 12 months postrandomization. Health-related quality of life was measured using the EuroQoL-5D-3L, Short Form 36 and Assessment of Quality of Life 4D at baseline, and at 6 and 12 months following randomization. Mortality data were available for 1,548 patients (97.3%) and 1,515 patients (95.2%) at 6 and 12 months, respectively. Health-related quality of life data were available for 85.1% of survivors at 12 months. There were no significant differences in mortality between groups at either 6 months (early goal-directed therapy 21.8% vs usual care 22.6%; p = 0.70) or 12 months (early goal-directed therapy 26.4% vs usual care 27.9%; p = 0.50). There were no group differences in health-related quality of life at either 6 or 12 months (EuroQoL-5D-3L utility scores at 12 mo early goal-directed therapy 0.65 ± 0.33 vs usual care 0.64 ± 0.34; p = 0.50), with the health-related quality of life of both groups being significantly lower than population norms.

CONCLUSIONS: In patients presenting to the emergency department with early septic shock, early goal-directed therapy compared with usual care did not reduce mortality nor improve health-related quality of life at either 6 or 12 months.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Higgins AM, Peake SL, Bellomo R, et al. Quality of Life and 1-Year Survival in Patients With Early Septic Shock: Long-Term Follow-Up of the Australasian Resuscitation in Sepsis Evaluation Trial. Crit Care Med. 2019. PMID: 30985391. doi:10.1097/CCM.0000000000003762

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。